Phil Taylor
$2.8 million Zynteglo gene therapy: Bluebird sets price on one-time beta-thalassemia treatment replacing red blood cell transfusions
Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA ...
